Anonymous
Guest
Anonymous
Guest
In today's news. Seekingalpha.com
With Mallinckrodt having its headquarters in Ireland, they are in a perfect position to be acquired by a foreign company looking for an inversion target. An example of how Mallinckrodt could use its strong balance sheet can be seen from the recent deal where Actavis, which is headquartered in Ireland, agreed to purchase Allergan, which is headquartered in the U.S. Actavis gained a strong drug portfolio, and will be able to lower the taxes that they have to pay on Allergan earnings. Mallinckrodt could selectively target companies that would fit in there product portfolio of specialty branded pharmaceuticals, and special generics.
Mallinckrodt would be an attractive acquisition target because of its strong growth potential, and because it is located in Ireland. This possibility would have been more feasible before regulations were implemented that made inversions more difficult to complete. If there were a company looking to try to invert, I believe Mallinckrodt would be the best target, because they have had the highest growth over the last five quarters. Using the Fidelity stock screener, I searched for healthcare companies located in Ireland that had a market capitalization of at least $5 billion. I found eight companies including Mallinckrodt that were located in Ireland and I looked at the revenue growth rate over the last five quarters. Included on the list of companies was Medtronic (NYSE:MDT), and because it recently inverted I excluded it from my list of Irish companies. As the table below shows Mallinckrodt has the highest revenue growth of the last five quarters, which I believe makes it an attractive acquisition target.
Company
Symbol
Quarterly Revenues
Growth Rate
ACTAVIS PLC
ACT
2,779
2,655
2,667
3,683
4,057
9.92%
ALKERMES PLC
ALKS
138.6
139.8
130.2
153.4
160
3.65%
ENDO INTERNATIONAL PLC
ENDP
661
585
595
719
764
3.69%
JAZZ PHARMACEUTICALS PLC
JAZZ
232.2
235.8
246.9
291.2
306.6
7.20%
MALLINCKRODT PLC
MNK
540
558
653
789
866
12.53%
PERRIGO CO PLC
PRGO
979
1,004
1,144
952
1,072
2.29%
SHIRE PLC
SHPG
1,261
1,347
1,502
1,597
1,576
5.73%
Valuation
With Mallinckrodt having its headquarters in Ireland, they are in a perfect position to be acquired by a foreign company looking for an inversion target. An example of how Mallinckrodt could use its strong balance sheet can be seen from the recent deal where Actavis, which is headquartered in Ireland, agreed to purchase Allergan, which is headquartered in the U.S. Actavis gained a strong drug portfolio, and will be able to lower the taxes that they have to pay on Allergan earnings. Mallinckrodt could selectively target companies that would fit in there product portfolio of specialty branded pharmaceuticals, and special generics.
Mallinckrodt would be an attractive acquisition target because of its strong growth potential, and because it is located in Ireland. This possibility would have been more feasible before regulations were implemented that made inversions more difficult to complete. If there were a company looking to try to invert, I believe Mallinckrodt would be the best target, because they have had the highest growth over the last five quarters. Using the Fidelity stock screener, I searched for healthcare companies located in Ireland that had a market capitalization of at least $5 billion. I found eight companies including Mallinckrodt that were located in Ireland and I looked at the revenue growth rate over the last five quarters. Included on the list of companies was Medtronic (NYSE:MDT), and because it recently inverted I excluded it from my list of Irish companies. As the table below shows Mallinckrodt has the highest revenue growth of the last five quarters, which I believe makes it an attractive acquisition target.
Company
Symbol
Quarterly Revenues
Growth Rate
ACTAVIS PLC
ACT
2,779
2,655
2,667
3,683
4,057
9.92%
ALKERMES PLC
ALKS
138.6
139.8
130.2
153.4
160
3.65%
ENDO INTERNATIONAL PLC
ENDP
661
585
595
719
764
3.69%
JAZZ PHARMACEUTICALS PLC
JAZZ
232.2
235.8
246.9
291.2
306.6
7.20%
MALLINCKRODT PLC
MNK
540
558
653
789
866
12.53%
PERRIGO CO PLC
PRGO
979
1,004
1,144
952
1,072
2.29%
SHIRE PLC
SHPG
1,261
1,347
1,502
1,597
1,576
5.73%
Valuation